Table 1A.
Subsample characteristics - demographics.
| Controls (N = 7293) | HT (N = 68) | TPOonly (N = 59) | Subclinical hypothyroidism (N = 331) | Subclinical hyperthyroidism (N = 276) | Overt hypothyroidism (N = 20) | Overt hyperthyroidism (N = 28) | |
|---|---|---|---|---|---|---|---|
| Age | 12.15 (3.35) | 14.16 (2.47)* | 13.73 (3.32)* | 11.02 (4.20)* | 11.00 (4.20)* | 10.54 (2.89) | 12.16 (4.22) |
| z-BMI | −0.03 (0.98) | 0.12 (1.03) | 0.16 (0.86) | 0.11 (1.07) | −0.11 (0.98) | 0.11 (1.04) | −0.32 (0.99) |
| Gender (female) | 48.1% | 77.9%* | 72.9%* | 46.2% | 48.2% | 45% | 60.7% |
| TPO positivity | 0%# | 100%# | 100%# | 7.3%* | 1.3%* | 27.8%* | 12.5%* |
| Levothyroxine | 0%# | 19.1%* | 0%#§ | 1.5%* | 0.4% | 0% | 14.3%* |
| Iodine | 0%# | 8.8%* | 0%# | 2.1%* | 0.4% | 0% | 3,6%* |
| Diagnosed thyroid disease | 0%# | 29.4%* | 0%#§ | 2.5%* | 2.3%* | 5%* | 21.4%* |
| Altered echogenicity | 0%# | 32.8% | 0%# | 0.9%+ | 0%+ | 5.3%+ | 3.6%+ |
| Irregularities US | 0%# | 35.3%* | 6.8%*§ | 2.4%* | 1.4%* | 15%* | 7.1%* |
| Psychotropic medication° | 1.4% | 0% | 1.8% | 0.6% | 1.9% | 5% | 0% |
| General health$ | 86.0% | 85.2% | 75.0% | 85.9% | 86.4% | 71.4% | 86.7% |
Mean and standard deviation in brackets or percentage.
*
Significant differences in comparison to healthy controls FDR-corrected at q < 0.05.
§
Significant mean difference in comparison to HT FDR-corrected at q < 0.05 (also compare to Table S3).
#
By definition,
+
not statistically evaluated additionally to irregularities on ultrasonography, §good or very good (parent-rated). °Does not include antiepileptics or phytopharmaceuticals. Note, irregularities on ultrasonography include altered echogenicity. US = ultrasonography.